Edition:
United Kingdom

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

37.75USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$37.75
Open
$37.85
Day's High
$38.30
Day's Low
$36.90
Volume
785,631
Avg. Vol
321,644
52-wk High
$42.60
52-wk Low
$7.70

Select another date:

Mon, Dec 4 2017

BRIEF-Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008

* ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME

BRIEF-Zogenix posts Q3 loss of $1.68 per share

* Zogenix provides corporate update and reports third quarter 2017 financial results

BRIEF-Zogenix announces closing of public offering of common stock

* Zogenix announces closing of public offering of common stock, including full exercise of underwriters’ option to purchase additional shares Source text for Eikon: Further company coverage:

BRIEF-Zogenix files for potential mixed shelf filing; size not disclosed - SEC filing‍​

* Files for potential mixed shelf filing; size not disclosed - SEC filing‍​ Source text : (http://bit.ly/2xOgvG9) Further company coverage:

Zogenix stock soars on epilepsy drug trial success

Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .

UPDATE 3-Zogenix stock soars on epilepsy drug trial success

* Analyst expects drug to become standard in Dravet treatment

BRIEF-Zogenix announces positive phase 3 clinical trial of ZX008 in Dravet syndrome

* Zogenix announces positive top-line results from pivotal phase 3 clinical trial of ZX008 in Dravet syndrome

Zogenix epilepsy drug meets main goal in late-stage trial

Sept 29 Zogenix Inc said on Friday its experimental treatment for a rare form of epilepsy met the main goal in a late-stage study.

BRIEF-Zogenix Q2 loss per share $0.93

* Zogenix provides corporate update and reports second quarter 2017 financial results

BRIEF-Zogenix and Durect Corp enter into termination agreement

* Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing

Select another date: